What is the plasma cofactor required by diuretics for direct vascular relaxant effect in vitro?

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 801-809

  Abrahams, Zuheir ^a   Pang, Monica Y M ^a   Lam, Eugene K ^a   Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Albumin; Chlorthalidone; Furosemide; Hydrochlorothiazide; Indapamide; Rat aortic rings

Indexed keywords

ALBUMIN; BOVINE SERUM ALBUMIN; CHLORTALIDONE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; OVALBUMIN;

ANIMAL TISSUE; AORTA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HYPERTENSION; NONHUMAN; PLASMA FACTOR; PRIORITY JOURNAL; RAT; TIME; VASCULAR RING; VASODILATATION;

EID: 0031832978     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00011     Document Type: Article

References (40)

1. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
2. Gerber JG, Nies AS. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Rall TW, Nies AS, Taylor P (editors): The pharmacological basis of therapeutics. Toronto: Pergamon Press Canada Ltd; 1990. pp. 784-807.
3. Freis ED. How do diuretics lower blood pressure? Am Heart J 1983; 106:185-187.
4. Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977; 22:499-504.
5. Conway J, Lauwers P. The hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960; 21:21-27.
6. Van Brummelen P, Man in 't Veld AJ, Schalekamp MADH. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980; 27: 328-336.
7. Calder JA, Schachter M, Sever PS. Vasorelaxant actions of thiazides and related drugs. Br J Pharmacol 1992; 105 (suppl):307P.
8. Calder JA, Schachter M, Sever P. Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol 1992: 220:19-26.
9. Abrahams Z, Tan LLY, Pang MYM, Abrahams B, Tan MM, Wright JM. Demonstration of an in vitro direct vascular relaxant effect of diuretics in the presence of plasma. J Hypertens 1996; 14:381-388.
10. Pillai G, Sutter MC. Effect of plasma from hypertensive patients on contractile response of vascular smooth muscle from normotensive rat. Can J Physiol Pharmacol 1989; 67:1272-1277.
11. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12:297-303.
12. Sabanathan K, Castleden CM, Adam HK, Ryan J, Fitzsimons TJ. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharmacol 1987; 32:53-60.
13. Beermann B, Groschinsky-Grind M. Clinical pharmacokinetics of diuretics. Clin Pharmacokinet 1980; 5:221-245.
14. Mroczek WJ. Indapamide: clinical pharmacology, therapeutic efficacy in hypertension and adverse effects. Pharmacotherapy 1983; 3:61-67.
15. Hammerland-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J Pharmacokinet Biopharm 1989; 17:1-46.
16. Andreasen F, Christensen JH. The effect of furosemide on vascular smooth muscle is influenced by plasma protein. Pharmacol Toxicol 1988; 63:324-326.
17. Morledge JH. Clinical efficacy and safety of indapamide in essential hypertension. Am Heart J 1983; 106:229-232.
18. Hatt PY, Leblond JB. A comparative study of the activity of a new agent, indapamide, in essential arterial hypertension. Curr Med Res Opin 1975; 3:138-144.
19. Witchitz S, Kamoun A, Chiche P. A double-blind study in hypertensive patients of an original new compound, indapamide. Curr Med Res Opin 1975; 3:1-8.
20. Barbhaiya RH, Patel RB, Corrick-West HP, Joslin RS, Welling PG. Comparative bioavailability and pharmacokinetics of hydrochlorothiazide from oral tablet dosage forms determined by plasma level and urinary excretion methods. Biopharm Drug Dispos 1982; 3:329-336.
21. Mirroneau J, Mirroneau C. Indapamide and vascular smooth muscle cells [review]. JAMA 1988; 4:31-33.
22. Andersson LO. Transport proteins. I. Serum albumin. A. Biochemistry. In: Blomback B, Hanson LA (editors): Plasma proteins. New York: J. Wiley & Sons; 1979. pp. 43-54.
23. Birke G, Liljedahl SO, Rothschild M. Transport proteins. I. Serum albumin. B. Physiology and clinical aspects. In: Blomback B, Hanson LA (editors): Plasma proteins. New York: J. Wiley & Sons; 1979. pp. 54-71.
24. Ghitescu L, Fixman A, Simionescu M, Simionescu N. Specific binding sites for albumin restricted to plasmalemmal vesicle of continuous capillary endothelium receptor-mediated transcytosis. J Cell Biol 1986; 102:1304-1311.
25. Kreye VAW, Bauer PK, Villhauer I. Evidence for furosemide-sensitive active chloride transport in vascular smooth muscle. Eur J Pharmacol 1981; 73:91-95.
26. Deth RC, Payne RA, Peecher DM. Influence of furosemide on rubidium-86 uptake and alpha-adrenergic response of arterial smooth muscle. Blood Vessels 1987; 24:321-333.
27. Gerstheimer FP, Muhleisen M, Nehring D, Kreye VA. A chloride-bicarbonate exchanging anion carrier in vascular smooth muscle of the rabbit. Eur J Physiol 1987; 409:60-66.
28. Greenberg S, McGowan C, Xie J, Summer WR. Selective pulmonary and venous smooth muscle relaxation by furosemide: a comparison with morphine. JPET 1994; 270:1077-1085.
29. Furchgott RF, Ponder E. Disk-sphere transformation in mammalian red cells, II. The nature of the anti-sphering factor. J Exp Biol 1940; 17:117-127.
30. Sellers EM, Koch-Weser J. Clinical implications of drug-albumin interaction. In: Rosender VM, Oratz M, Rothschild MA (editors): Albumin structure, function, and uses. New York: Pergamon Press; 1977. pp. 60-85.
31. Dromgoole SH. The binding capacity of albumin and renal disease. J Pharmacol Exp Ther 1974; 191:318-323.
32. Andreasen F. Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 1973; 32:417-429.
33. Anton AH, Corey WT. Interindividual differences in the protein binding of sulfonamides: the effect of disease and drugs. Acta Pharmacol Toxicol 1971; 29 (suppl 3):134-151.
34. Campion DS. Decreased drug binding by serum albumin during renal failure. Toxicol Appl Pharmacol 1973; 25:391-397.
35. Andreasen F. The effect of dialysis on the protein binding of drugs in the plasma of patients with acute renal failure. Acta Pharmacol Toxicol 1973; 34:284-294.
36. Adler DS, Martin E, Gamertoglio JG, Tozer TN, Spire JP. Hemodialysis of phenytoin in a uremic patient. Clin Pharmacol Ther 1975; 18:65-69.
37. Franklin SS, Weber MA. Measuring hypertensive cardiovascular risk: the vascular overload concept. Am Heart J 1994; 128:793-803.
38. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
39. Pape D, Beuchard J, Guillo P, Allain H, Bellissant E. Hypoxic contractile response in isolated rat thoracic aorta: role of endothelium, extracellular calcium and endothelin. Fundamental Clin Pharmacol 1997, 11:121-126.
40. Gräser T, Rubanyi GM. Different mechanisms of hypoxic relaxation in canine coronary arteries and rat abdominal aortas. J Cardiovasc Pharmacol 1992; 20 (suppl 12):S117-S119.